Nevirapine-Induced Hepatotoxicity and Pharmacogenetics: A Retrospective Study in a Population from Mozambique

• Owen A , PirmohamedM, KhooSH, BackDJ: Pharmacogenetics of HIV therapy.Pharmacogenet. Genomics16 , 693–703 (2006).
   PubMed Web of Science ®Google Scholar
• Nolan ML , GreenbergAE, FowlerMG: A review of clinical trials to prevent mother-to-child HIV-1 transmission in Africa and inform rational intervention strategies.AIDS16 , 1991–1999 (2002).
   PubMed Web of Science ®Google Scholar
• Stern JO , RobinsonPA, LoveJ, LanesS, ImperialeMS, MayersDL: A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients.J. Acquir. Immune Defic. Syndr.34 , S21–S33 (2003)
   PubMed Web of Science ®Google Scholar
• Martinez E , BlancoJL, ArnaizJA et al.: Hepatoxicity in HIV-1 infected patients receiving nevirapine-containing antiretroviral therapy.AIDS15 , 1261–1268 (2001).
   PubMed Web of Science ®Google Scholar
• Shakil A , KramerD, MazariegosG, FungJJ, RakelaJ: Acute liver failure: clinical features, outcome analysis, and applicability of prognostic criteria.Liver Transpl.6 , 163–169 (2000).
   PubMed Web of Science ®Google Scholar
• Marazzi MC , GermanoP, LiottaG et al.: Safety of nevirapine-containing antiretroviral triple therapy regimens to prevent vertical transmission in an African cohort of HIV-1-infected pregnant women.HIV Med.7 , 338–344 (2006).
   PubMed Web of Science ®Google Scholar
• Dieterich DT , RobinsonPA, LoveJ, SternJO: Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors.Clin. Infect. Dis.38(Suppl. 2) , S80–S89 (2004).
   PubMed Web of Science ®Google Scholar
• Fellay J , MarzoliniC, MeadenER et al.: Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study.Lancet359(9300) , 30–36 (2002).
   PubMed Web of Science ®Google Scholar
• Rotger M , ColomboS, FurrerH et al.: Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients.Pharmacogenet. Genomics15(1) , 1–5 (2005).
   PubMedGoogle Scholar
• Haas DW , RibaudoHJ, KimRB et al.: Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study.AIDS18(18) , 2391–2400 (2004).
   PubMed Web of Science ®Google Scholar
• Ramachandran G , Hemanth Kumar AK, Rajasekaran S et al.: CYP2B6 G516T polymorphism but not rifampicin co-administration influence steady state pharmacokinetics of efavirenz in HIV-infected patients in south India. Antimicrob. Agents Chemother.53(3) , 863–868 (2009).
   PubMed Web of Science ®Google Scholar
• Haas DW , BartlettJA, AndersenJW et al.: Adult AIDS Clinical Trials Group. Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration.Clin. Infect. Dis.43(6) , 783–786 (2006).
   PubMed Web of Science ®Google Scholar
• Martin AM , NolanD, JamesI et al.: Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts.AIDS19(1) , 97–99 (2005).
   PubMed Web of Science ®Google Scholar
• Saitoh A , SarlesE, CapparelliE et al.: CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children.AIDS21(16) , 2191–2199 (2007).
   PubMed Web of Science ®Google Scholar
• Excoffier L , LavalG, SchneiderS: An integrated software for population genetics data analysis.Evol. Bioinform. Online1 , 47–50 (2005)
   PubMed Web of Science ®Google Scholar
• Rodriguez-Novoa S , BarreiroP, RendónA, Jiménez-NacherI, González-LahozJ, SorianoV: Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects.Clin. Infect. Dis.40(9) , 1358–1361 (2005).
   PubMed Web of Science ®Google Scholar
• Lang T , KleinK, FischerJ et al.: Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver.Pharmacogenetics11 , 399–415 (2001).
   PubMedGoogle Scholar
• Mehlotra RK , BockarieMJ, ZimmermanPA: CYP2B6 983T>C polymorphism is prevalent in West Africa but absent in Papua New Guinea: implications for HIV/AIDS treatment.Br. J. Clin. Pharmacol.64(3) , 391–395 (2007).
   PubMed Web of Science ®Google Scholar
• Wyen C , HendraH, VogelM et al.: Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients.J. Antimicrob. Chemother.61(4) , 914–918 (2008).
   PubMed Web of Science ®Google Scholar
• Hoffmeyer S , BurkO, von Richter O et al.: Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl Acad. Sci. USA97 , 3473–3478 (2000).
   PubMed Web of Science ®Google Scholar
• Johne A , KöpkeK, GerloffT et al.: Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene.Clin. Pharmacol. Ther.72(5) , 584–594 (2002).
   PubMed Web of Science ®Google Scholar
• Kim RB , LeakeBF, ChooEF et al.: Identification of functionally variant MDR1 alleles among European Americans and African Americans.Clin. Pharmacol. Ther.70(2) , 189–199 (2001).
   PubMed Web of Science ®Google Scholar
• Wang D , SadéeW: Searching for polymorphisms that affect gene expression and mRNA processing: example ABCB1 (MDR1).AAPS J.8(3) , E515–E520 (2006).
   PubMed Web of Science ®Google Scholar

▪ Websites

• The National Council to Combat AIDS www.cncs.org.mz/cncs.htm
   Google Scholar
• DREAM: an integrated faith-based initiative to treat HIV/AIDS in Mozambique www.who.int/hiv/pub/casestudies/mozambiquedream.pdf
   Google Scholar
• Division of AIDS Table for Grading Severity of Adult Adverse Experiences http://rcc.tech-res.com/Document/safetyandpharmacovigilance/ToxicityTables_Adult_TRP_v01a.pdf
   Google Scholar